ATE293599T1 - Indolderivate als faktor xa inhibitoren - Google Patents

Indolderivate als faktor xa inhibitoren

Info

Publication number
ATE293599T1
ATE293599T1 AT98965244T AT98965244T ATE293599T1 AT E293599 T1 ATE293599 T1 AT E293599T1 AT 98965244 T AT98965244 T AT 98965244T AT 98965244 T AT98965244 T AT 98965244T AT E293599 T1 ATE293599 T1 AT E293599T1
Authority
AT
Austria
Prior art keywords
inhibitors
factor
indole derivatives
indole
derivatives
Prior art date
Application number
AT98965244T
Other languages
English (en)
Inventor
Elisabeth Defossa
Uwe Heinelt
Otmar Klingler
Gerhard Zoller
Fahad Al-Obeidi
Armin Walser
Peter Wildgoose
Hans Matter
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of ATE293599T1 publication Critical patent/ATE293599T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
AT98965244T 1997-12-24 1998-12-10 Indolderivate als faktor xa inhibitoren ATE293599T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97122901 1997-12-24
PCT/EP1998/008030 WO1999033800A1 (en) 1997-12-24 1998-12-10 Indole derivatives as inhibitors or factor xa

Publications (1)

Publication Number Publication Date
ATE293599T1 true ATE293599T1 (de) 2005-05-15

Family

ID=8227884

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98965244T ATE293599T1 (de) 1997-12-24 1998-12-10 Indolderivate als faktor xa inhibitoren

Country Status (29)

Country Link
US (1) US6337344B1 (de)
EP (1) EP1042287B1 (de)
JP (1) JP4589529B2 (de)
KR (1) KR100608472B1 (de)
CN (1) CN1220681C (de)
AR (1) AR018031A1 (de)
AT (1) ATE293599T1 (de)
AU (1) AU743881B2 (de)
BR (1) BR9814340B1 (de)
CA (1) CA2316172C (de)
CZ (1) CZ298827B6 (de)
DE (1) DE69829879T2 (de)
DK (1) DK1042287T3 (de)
ES (1) ES2241194T3 (de)
HK (1) HK1033795A1 (de)
HU (1) HU227568B1 (de)
ID (1) ID27044A (de)
IL (1) IL136954A0 (de)
MY (1) MY120064A (de)
NO (1) NO316912B1 (de)
NZ (1) NZ505370A (de)
PL (1) PL195682B1 (de)
PT (1) PT1042287E (de)
RU (1) RU2225397C2 (de)
SI (1) SI1042287T1 (de)
TR (1) TR200001954T2 (de)
TW (1) TWI241294B (de)
WO (1) WO1999033800A1 (de)
ZA (1) ZA9811759B (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
DE69829879T2 (de) * 1997-12-24 2006-03-02 Sanofi-Aventis Deutschland Gmbh Indolderivate als faktor xa inhibitoren
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
DE19917504A1 (de) * 1999-04-17 2000-10-19 Dresden Arzneimittel Verwendung von Hydroxyindolen, die Inhibitoren der Phosphodiesterase 4 sind, zur Therapie chronisch obstruktiver Lungenerkrankungen
WO2000040571A1 (en) 1999-01-02 2000-07-13 Aventis Pharma Deutschland Gmbh Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)
IL144095A0 (en) 1999-01-02 2002-05-23 Aventis Pharma Gmbh Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
GB9902461D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
AR024158A1 (es) * 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
EP1095933A1 (de) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH N-Guanidinoalkylamide, Verfahren zu ihrer Herstellung, ihre Verwendung und pharmazeutische Zusammensetzungen, die sie enthalten
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
EP1127884A1 (de) 2000-02-26 2001-08-29 Aventis Pharma Deutschland GmbH Neue Malonsäure Derivaie, Verfahren zu ihrer Herstellung, ihre Verwendung als Inhibitor der Faktor XA Aktivtät und pharmazeutische Zusammensetzungen diese enthaltend
GB0005366D0 (en) * 2000-03-06 2000-04-26 Xenova Ltd Pharmaceutical compounds
EP1272483A2 (de) * 2000-03-24 2003-01-08 Millenium Pharmaceuticals, Inc. Oxindole als faktor xa inhibitoren
AU2001271531A1 (en) * 2000-06-27 2002-01-08 Smith Kline Beecham Corporation Fatty acid synthase inhibitors
WO2002026712A2 (en) * 2000-09-29 2002-04-04 Millennium Pharmaceuticals, Inc. Quaternary amines and related inhibitors of factor xa
TNSN03146A1 (fr) 2001-06-28 2005-12-23 Pfizer Prod Inc Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipo-proteine b (apo b).
DE10147672A1 (de) * 2001-09-27 2003-04-10 Bayer Ag Substituierte 2,5-Diamidoindole und ihre Verwendung
EP1314733A1 (de) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indol-2-carbonsäureamide als Faktor-Xa-Hemmer
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
WO2004050637A2 (en) 2002-12-03 2004-06-17 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
EP1479677A1 (de) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Neue Indolderivate als Faktor Xa-Inhibitoren
US7317027B2 (en) * 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1479680A1 (de) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole-Derivative als Faktor Xa Hemmer
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
SE0302035D0 (sv) * 2003-07-09 2003-07-09 Biolipox Ab New compound
US7348338B2 (en) * 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
UA88767C2 (uk) * 2003-07-17 2009-11-25 Плексікон, Інк. Ppar активні сполуки
US7186084B2 (en) * 2003-11-19 2007-03-06 General Electric Company Hot gas path component with mesh and dimpled cooling
EP1568698A1 (de) * 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrolderivate als faktor-xa-inhibitoren
US7705023B2 (en) 2004-06-18 2010-04-27 Biolipox Ab Indoles useful in the treatment of inflammation
EP1765775B1 (de) * 2004-06-18 2009-04-29 Biolipox AB Zur behandlung von entzündungen geeignete indole
MXPA06014536A (es) * 2004-06-18 2007-06-05 Biolipox Ab Indoles utiles en el tratamiento de inflamacion.
WO2006027135A1 (en) * 2004-09-06 2006-03-16 F. Hoffmann-La Roche Ag 4-aminomethyl benzamidine derivatives and their use as factor viiia inhibitors
AU2005299693B2 (en) 2004-10-26 2012-07-05 Janssen Pharmaceutica, N.V. Factor Xa compounds
GB0428173D0 (en) * 2004-12-23 2005-01-26 Astrazeneca Ab Compounds
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US20100197687A1 (en) * 2005-01-19 2010-08-05 Benjamin Pelcman Indoles Useful in the Treatment of Inflammation
US20090048285A1 (en) * 2005-01-19 2009-02-19 Benjamin Pelcman Pyrrolopyridines Useful in the Treatment of Inflammation
EP1838669A1 (de) * 2005-01-19 2007-10-03 Biolipox AB Entzündungshemmende indol-derivate
US20090069384A1 (en) * 2005-01-19 2009-03-12 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
CA2594878A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
MX2007008759A (es) 2005-01-19 2007-09-11 Biolipox Ab Indoles utiles en el tratamiento de la inflamacion.
CA2601777A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1747779A1 (de) 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolinsulfonamid-Derivate als 5-HT6 Liganden
NZ567162A (en) * 2005-09-07 2011-06-30 Plexxikon Inc 1, 3-disubstituted indole derivatives for use as PPAR modulators
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
AU2007297013B2 (en) * 2006-09-13 2012-05-31 Sanofi-Aventis Isoserine derivatives for use as coagulation factor IXa inhibitors
ES2452343T3 (es) * 2006-09-29 2014-04-01 Glaxosmithkline Llc Compuestos de indol sustituidos
CN101535253A (zh) 2006-11-09 2009-09-16 弗·哈夫曼-拉罗切有限公司 吲哚和苯并呋喃2-甲酰胺衍生物
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
NZ582056A (en) * 2007-08-10 2012-08-31 Lundbeck & Co As H Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation
AU2009239430B2 (en) 2008-04-21 2015-01-22 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
CN101654427B (zh) * 2008-08-19 2012-12-05 信谊药厂 抗凝化合物、组合物及其用途
WO2011044134A1 (en) 2009-10-05 2011-04-14 Albany Molecular Research, Inc. Epiminocycloalkyl(b)indole derivatives as serotonin sub-type 6 (5-ht6) modulators and uses thereof
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
SG10201408429UA (en) 2009-12-18 2015-02-27 Activesite Pharmaceuticals Inc Prodrugs of inhibitors of plasma kallikrein
EP2668191A4 (de) 2011-01-19 2014-08-20 Albany Molecular Res Inc Benzofuro-[3,2-c-]pyridine und verwandte analoga als serotonin-untertyp-6 (5-ht6)-modulatoren zur behandlung von adipositas, stoffwechselsyndrom, kognition und schizophrenie
US9353113B2 (en) 2011-03-18 2016-05-31 Ono Pharmaceutical Co., Ltd. Tetrahydrocarboline derivative
US8691861B2 (en) 2011-04-13 2014-04-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2017123826A1 (en) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
CN111655257A (zh) * 2017-11-10 2020-09-11 密歇根大学董事会 Ash1l抑制剂及用其进行治疗的方法
WO2023068700A1 (ko) * 2021-10-20 2023-04-27 동국대학교 와이즈캠퍼스 산학협력단 두룸아마이드 a를 포함하는 혈소판 응집 예방, 개선 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529724A (en) * 1983-10-11 1985-07-16 Mcneilab, Inc. 6H-indolo[2,1-c][1,4]benzodiazepines and 12-oxo derivatives useful as antihypertensives
DD235866B1 (de) 1985-03-29 1988-12-28 Univ Leipzig Verfahren zur herstellung von n alpha (2-naphthyl)-sulfonylaminoacylierten amidinophenylalanisamiden
AU707653B2 (en) 1994-04-26 1999-07-15 Selectide Corporation Factor Xa inhibitors
US5612363A (en) * 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
DE19530996A1 (de) 1995-08-23 1997-02-27 Boehringer Mannheim Gmbh Cyclische Guanidine, Verfahren zu ihrer Herstellung und Arzneimittel
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
CA2244851A1 (en) * 1996-02-22 1997-08-28 Petrus Fredericus Wilhelmus Stouten M-amidino phenyl analogs as factor xa inhibitors
US6200969B1 (en) * 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
DE69829879T2 (de) * 1997-12-24 2006-03-02 Sanofi-Aventis Deutschland Gmbh Indolderivate als faktor xa inhibitoren

Also Published As

Publication number Publication date
DE69829879T2 (de) 2006-03-02
CZ298827B6 (cs) 2008-02-20
IL136954A0 (en) 2001-06-14
HUP0100723A2 (hu) 2001-08-28
JP2001527066A (ja) 2001-12-25
AR018031A1 (es) 2001-10-31
AU743881B2 (en) 2002-02-07
HUP0100723A3 (en) 2002-12-28
CA2316172C (en) 2010-02-02
EP1042287A1 (de) 2000-10-11
CA2316172A1 (en) 1999-07-08
TR200001954T2 (tr) 2000-12-21
PL341400A1 (en) 2001-04-09
CZ20002310A3 (cs) 2000-10-11
BR9814340A (pt) 2000-10-03
NO20003057L (no) 2000-08-18
US6337344B1 (en) 2002-01-08
NO20003057D0 (no) 2000-06-14
AU2052899A (en) 1999-07-19
NZ505370A (en) 2002-06-28
KR20010033573A (ko) 2001-04-25
WO1999033800A1 (en) 1999-07-08
DK1042287T3 (da) 2005-08-15
ES2241194T3 (es) 2005-10-16
CN1283186A (zh) 2001-02-07
HK1033795A1 (en) 2001-09-21
PL195682B1 (pl) 2007-10-31
NO316912B1 (no) 2004-06-21
KR100608472B1 (ko) 2006-08-09
CN1220681C (zh) 2005-09-28
JP4589529B2 (ja) 2010-12-01
EP1042287B1 (de) 2005-04-20
HU227568B1 (en) 2011-08-29
ZA9811759B (en) 1999-07-28
DE69829879D1 (de) 2005-05-25
BR9814340B1 (pt) 2010-07-13
MY120064A (en) 2005-08-30
SI1042287T1 (en) 2005-10-31
RU2225397C2 (ru) 2004-03-10
TWI241294B (en) 2005-10-11
ID27044A (id) 2001-02-22
PT1042287E (pt) 2005-08-31

Similar Documents

Publication Publication Date Title
DE69829879D1 (de) Indolderivate als faktor xa inhibitoren
ATE243681T1 (de) Benzamidinderivate als faktor xa-inhibitoren
ATE302198T1 (de) Guanidine imitatoren als faktor xa inhibitoren
NO20021230D0 (no) Inhibitorer for faktor Xa
NO20003808D0 (no) Substituerte oksoazaheterosyklylfaktor Xa inhibitorer
ATE443698T1 (de) Stickstoffhaltige heterocyclen als faktor xa- hemmer
ATE251612T1 (de) 6-phenylpyridyl-2-amin-derivate verwendbar als nos-inhibitoren
DK0915088T3 (da) D-prolinderivater
NO20013072D0 (no) Nitrogenholdige heterocykler som faktor Xa-inhibitorer
HUP0002528A3 (en) Heterocyclic derivatives which inhibit factor xa
ATE278695T1 (de) Piperidinderivate
ATE289294T1 (de) Pyrrolidin-derivate als faktor xa inhibitoren
ATE240317T1 (de) Indolderivate als pkc-inhibitoren
DK1189583T3 (da) Indolderivater
IS6434A (is) Nýjar indól afleiður
NO20020306D0 (no) Indolderivater
NO20001778D0 (no) Substituerte piperidinderivater
AU4900397A (en) Heterocyclic derivatives as factor xa inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1042287

Country of ref document: EP